- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Somatic alterations in human cancer genomes
Matthew L. Meyerson
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Challenges and opportunities for genomic medicine
P. Andrew Futreal
UT MD Anderson Cancer Ctr., Houston, TX, United States
- Free
- audio + slides
- Some slides withheld
Advances and future of finding cancer associated genes
Gad Getz
Broad Inst. of MIT and Harvard, Cambridge, MA, United States
- Permission not
granted for presentation
BRAF and RAS signaling in melanoma: From basic biology to clinical exploitation
Richard M. Marais
Cancer Research UK Manchester Institute, Manchester, United Kingdom
- Free
- Unknown permission
for presentation
Title to be announced
Neal Rosen
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
- Permission not
granted for presentation
Matrix-dependent adaptive resistance to targeted therapy
Joan S. Brugge
Harvard Medical School, Boston, MA, United States
- Permission not
granted for presentation
Welcome and Opening Remarks
Jeffrey A. Engelman
Massachusetts General Hospital, Charlestown, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Wnt signaling, Lgr5 stem cells, and cancer
Hans Clevers
Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences & University Medical Centre, Utrecht, Netherlands
- Permission not
granted for presentation
Targeting the PD-1 pathway: Resetting the balance between the immune system and cancer
Suzanne L. Topalian
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Using synthetic lethality to find effective combination therapies for cancer
René Bernards
Netherlands Cancer Inst., Amsterdam, Netherlands
- Free
- audio only
- Audio only
Mechanisms of resistance to RAF/MEK inhibitors
David B. Solit
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
- Free
- audio + slides
- Some slides withheld
Overcoming acquired resistance to first-generation kinase inhibitors in lung cancer
William Pao
Vanderbilt Univ., Nashville, TN, United States
- Free
- audio + slides
- Some slides withheld
Mechanisms of acquired resistance to ALK/ROS1 inhibitors
Alice T. Shaw
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
- Permission not
granted for presentation
The metabolic phase of the cell cycle
Eyal Gottlieb
Cancer Research UK, Beatson Institute, Glasgow, United Kingdom
- Free
- audio + slides
- Some slides withheld
The genetic basis of kidney cancer: A metabolic disease
W. Marston Linehan
National Cancer Inst., Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Ras-induced macropinocytosis: Metabolic adaptation to signaling in the absence of adequate nutrients
Craig B. Thompson
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
- Permission not
granted for presentation
IDH mutations and tumorigenicity
Katharine E. Yen
Agios Pharmaceuticals, Cambridge, MA, United States
- Free
- audio only
- Audio only
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael Burns
Vanderbilt University School of Medicine, Nashville, TN, United States
- Permission not
granted for presentation
LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6-- Reactivating Rb in cancer
Sunkyu Kim
Novartis Institutes for Biomedical Research, Cambridge, MA, United States
- Permission not
granted for presentation
Selective sensitization of mutant K-Ras cancer cells to DNA damage based therapies by targeting wild type H- and N-Ras
Elda Grabocka
NYU Langone Medical Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition
Katherine Hutchinson
Vanderbilt University, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
Working together to identify new epigenetic targets for cancer
Chas Bountra
University of Oxford, Oxford, United Kingdom
- Permission not
granted for presentation
Targeting enhancers in cancers
James E. Bradner
Dana-Farber Cancer Inst., Boston, MA, United States
- Permission not
granted for presentation
Designing p300/CBP histone acetyltransferase inhibitors for cancer
Philip A. Cole
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Protein methyltransferase inhibitors as personalized cancer therapeutics
Robert A. Copeland
Epizyme, Inc., Cambridge, MA, United States